A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy

NCT00189358 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Ovarian Cancer
Cancer of the Fallopian Tube
Peritoneal Cancer

Interventions

DRUG: ZD1839
DRUG: tamoxifen

Sponsor

AGO Study Group